Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma

S. Fuji, H. Fujiwara, N. Nakano, A. Wake, Y. Inoue, T. Fukuda, M. Hidaka, Y. Moriuchi, T. Miyamoto, N. Uike, J. Taguchi, T. Eto, T. Tomoyose, T. Kondo, A. Yamanoha, T. Ichinohe, Y. Atsuta, A. Utsunomiya

研究成果: ジャーナルへの寄稿学術誌査読

35 被引用数 (Scopus)

抄録

Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.

本文言語英語
ページ(範囲)205-211
ページ数7
ジャーナルBone Marrow Transplantation
51
2
DOI
出版ステータス出版済み - 2月 1 2016

!!!All Science Journal Classification (ASJC) codes

  • 血液学
  • 移植

フィンガープリント

「Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル